Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 91 articles:
HTML format

Single Articles

    June 2022
  1. MARTIN P, Cohen JB, Wang M, Kumar A, et al
    Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
    J Clin Oncol. 2022 Jun 28:JCO2102698. doi: 10.1200/JCO.21.02698.
    PubMed     Abstract available

  2. WANG M, Munoz J, Goy A, Locke FL, et al
    Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    J Clin Oncol. 2022 Jun 4:JCO2102370. doi: 10.1200/JCO.21.02370.
    PubMed     Abstract available

    April 2022
  3. CHANG A, Akhtar A, Linderman SL, Lai L, et al
    Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Apr 18:JCO2200088. doi: 10.1200/JCO.22.00088.
    PubMed     Abstract available

  4. LAKHOTIA R, Melani C, Roschewski M, Wilson WH, et al
    Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
    J Clin Oncol. 2022 Apr 4:JCO2102593. doi: 10.1200/JCO.21.02593.

    March 2022
  5. MIKHAEEL NG, Heymans MW, Eertink JJ, de Vet HCW, et al
    Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.
    J Clin Oncol. 2022 Mar 31:JCO2102063. doi: 10.1200/JCO.21.02063.
    PubMed     Abstract available

  6. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    PubMed     Abstract available

  7. SHIBUSAWA M, Kusumi E, Murakami J, Tanimoto T, et al
    Response-Adapted Postinduction Strategy in Follicular Lymphoma.
    J Clin Oncol. 2022 Mar 11:JCO2102818. doi: 10.1200/JCO.21.02818.

  8. TEACHEY DT, Devidas M, Wood BL, Chen Z, et al
    Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200/JCO.21.02678.
    PubMed     Abstract available

    Turning Point.
    J Clin Oncol. 2022;40:801-802.

    February 2022
  10. ADVANI AS, Moseley A, O'Dwyer KM, Wood BL, et al
    SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Feb 14:JCO2101766. doi: 10.1200/JCO.21.01766.
    PubMed     Abstract available

  11. BUDDE LE, Assouline S, Sehn LH, Schuster SJ, et al
    Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
    J Clin Oncol. 2022;40:481-491.
    PubMed     Abstract available

    January 2022
  12. CASULO C
    Response-Adapted Therapy in Follicular Lymphoma: At the Threshold of a Precision Approach.
    J Clin Oncol. 2022 Jan 25:JCO2102477. doi: 10.1200/JCO.21.02477.

  13. LAGERLOF I, Fohlin H, Enblad G, Glimelius B, et al
    Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.
    J Clin Oncol. 2022 Jan 25:JCO2102407. doi: 10.1200/JCO.21.02407.
    PubMed     Abstract available

  14. LOUARN N, Galicier L, Bertinchamp R, Lussato D, et al
    First Extensive Analysis of (18)F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Affects Prognosis.
    J Clin Oncol. 2022 Jan 24:JCO2101228. doi: 10.1200/JCO.21.01228.
    PubMed     Abstract available

  15. GINE E, de la Cruz F, Jimenez Ubieto A, Lopez Jimenez J, et al
    Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    J Clin Oncol. 2022 Jan 14:JCO2102321. doi: 10.1200/JCO.21.02321.
    PubMed     Abstract available

  16. CASASNOVAS RO, Bouabdallah R, Brice P, Lazarovici J, et al
    Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
    J Clin Oncol. 2022 Jan 6:JCO2101777. doi: 10.1200/JCO.21.01777.
    PubMed     Abstract available

    December 2021
  17. SHOUVAL R, Alarcon Tomas A, Fein JA, Flynn JR, et al
    Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
    J Clin Oncol. 2021 Dec 3:JCO2102143. doi: 10.1200/JCO.21.02143.
    PubMed     Abstract available

    November 2021
    Moving Beyond One Size Fits All for T-Cell Lymphoma.
    J Clin Oncol. 2021 Nov 29:JCO2102463. doi: 10.1200/JCO.21.02463.

  19. BACHY E, Camus V, Thieblemont C, Sibon D, et al
    Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    J Clin Oncol. 2021 Nov 29:JCO2101815. doi: 10.1200/JCO.21.01815.
    PubMed     Abstract available

  20. JAIN P, Zhao S, Lee HJ, Hill HA, et al
    Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    J Clin Oncol. 2021 Nov 19:JCO2101797. doi: 10.1200/JCO.21.01797.
    PubMed     Abstract available

    October 2021
  21. LUMINARI S, Manni M, Galimberti S, Versari A, et al
    Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
    J Clin Oncol. 2021 Oct 28:JCO2101234. doi: 10.1200/JCO.21.01234.
    PubMed     Abstract available

    September 2021
  22. BURKE GAA, Minard-Colin V, Auperin A, Alexander S, et al
    Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.
    J Clin Oncol. 2021 Sep 27:JCO2100920. doi: 10.1200/JCO.21.00920.
    PubMed     Abstract available

  23. FRANK MJ, Hossain NM, Bukhari A, Dean E, et al
    Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
    J Clin Oncol. 2021;39:3034-3043.
    PubMed     Abstract available

    August 2021
    Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress.
    J Clin Oncol. 2021 Aug 24:JCO2101552. doi: 10.1200/JCO.21.01552.
    PubMed     Abstract available

  25. CUTTER DJ, Ramroth J, Diez P, Buckle A, et al
    Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2021 Aug 13:JCO2100408. doi: 10.1200/JCO.21.00408.
    PubMed     Abstract available

    June 2021
  26. OVLISEN AK, Jakobsen LH, Eloranta S, Kragholm KH, et al
    Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study.
    J Clin Oncol. 2021 Jun 25:JCO2100357. doi: 10.1200/JCO.21.00357.
    PubMed     Abstract available

  27. MOSKOWITZ AJ, Shah G, Schoder H, Ganesan N, et al
    Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jun 25:JCO2101056. doi: 10.1200/JCO.21.01056.
    PubMed     Abstract available

  28. DEMEESTERE I, Racape J, Dechene J, Dupuis J, et al
    Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).
    J Clin Oncol. 2021 Jun 22:JCO2100068. doi: 10.1200/JCO.21.00068.
    PubMed     Abstract available

    May 2021
  29. SMITH SD, Gopal AK
    Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL.
    J Clin Oncol. 2021;39:1671-1673.

    April 2021
  30. ALIG S, Macaulay CW, Kurtz DM, Duhrsen U, et al
    Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2002573. doi: 10.1200/JCO.20.02573.
    PubMed     Abstract available

  31. KUMAR A, Casulo C, Advani RH, Budde E, et al
    Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2100108. doi: 10.1200/JCO.21.00108.
    PubMed     Abstract available

  32. SHAW BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, et al
    National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
    J Clin Oncol. 2021 Apr 27:JCO2003502. doi: 10.1200/JCO.20.03502.
    PubMed     Abstract available

    Precision Medicine in DLBCL: Are We There Yet?
    J Clin Oncol. 2021;39:1314-1316.

  34. SMITH SM
    Improving Survival and Predicting Toxicity in Older Patients With DLBCL: A Delicate Balance.
    J Clin Oncol. 2021;39:1193-1195.

  35. METZGER ML, Link MP, Billett AL, Flerlage J, et al
    Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
    J Clin Oncol. 2021 Apr 7:JCO2003286. doi: 10.1200/JCO.20.03286.
    PubMed     Abstract available

  36. RAMER SJ
    This Is Not Happening.
    J Clin Oncol. 2021;39:1162-1164.

    March 2021
  37. HUTCHINGS M, Morschhauser F, Iacoboni G, Carlo-Stella C, et al
    Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    J Clin Oncol. 2021 Mar 19:JCO2003175. doi: 10.1200/JCO.20.03175.
    PubMed     Abstract available

  38. FOWLER NH, Samaniego F, Jurczak W, Ghosh N, et al
    Umbralisib, a Dual PI3Kdelta/CK1epsilon Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2021 Mar 8:JCO2003433. doi: 10.1200/JCO.20.03433.
    PubMed     Abstract available

    February 2021
  39. OEFFINGER KC, Stratton KL, Hudson MM, Leisenring WM, et al
    Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2021 Feb 25:JCO2001186. doi: 10.1200/JCO.20.01186.
    PubMed     Abstract available

  40. NOWAKOWSKI GS, Chiappella A, Gascoyne RD, Scott DW, et al
    ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2021 Feb 23:JCO2001366. doi: 10.1200/JCO.20.01366.
    PubMed     Abstract available

  41. MERLI F, Luminari S, Tucci A, Arcari A, et al
    Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi.
    J Clin Oncol. 2021 Feb 12:JCO2002465. doi: 10.1200/JCO.20.02465.
    PubMed     Abstract available

  42. HESLOP HE, Sharma S, Rooney CM
    Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.
    J Clin Oncol. 2021;39:514-524.

  43. AOKI T, Savage KJ, Steidl C
    Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers.
    J Clin Oncol. 2021;39:346-360.

  44. NOWAKOWSKI GS, Hong F, Scott DW, Macon WR, et al
    Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
    J Clin Oncol. 2021 Feb 8:JCO2001375. doi: 10.1200/JCO.20.01375.
    PubMed     Abstract available

  45. KHURANA A, Mwangi R, Nowakowski GS, Habermann TM, et al
    Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
    J Clin Oncol. 2021 Feb 2:JCO2001935. doi: 10.1200/JCO.20.01935.
    PubMed     Abstract available

    January 2021
  46. VASILEIOU S, Lulla PD, Tzannou I, Watanabe A, et al
    T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
    J Clin Oncol. 2021 Jan 28:JCO2002224. doi: 10.1200/JCO.20.02224.
    PubMed     Abstract available

  47. OLSZEWSKI AJ, Jakobsen LH, Collins GP, Cwynarski K, et al
    Burkitt Lymphoma International Prognostic Index.
    J Clin Oncol. 2021 Jan 27:JCO2003288. doi: 10.1200/JCO.20.03288.
    PubMed     Abstract available

  48. OBERIC L, Peyrade F, Puyade M, Bonnet C, et al
    Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
    J Clin Oncol. 2021 Jan 14:JCO2002666. doi: 10.1200/JCO.20.02666.
    PubMed     Abstract available

    Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jan 12:JCO2001749. doi: 10.1200/JCO.20.01749.

  50. SHAH NN, Hamadani M
    Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?
    J Clin Oncol. 2021 Jan 12:JCO2001447. doi: 10.1200/JCO.20.01447.

    Checkpoint BLOCKade in Lymphoma.
    J Clin Oncol. 2021 Jan 12:JCO2001522. doi: 10.1200/JCO.20.01522.

  52. LUSSANA F, Gritti G, Rambaldi A
    Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    J Clin Oncol. 2021 Jan 12:JCO2001564. doi: 10.1200/JCO.20.01564.

  53. ALENCAR AJ, Moskowitz CH
    Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jan 12:JCO2001751. doi: 10.1200/JCO.20.01751.

    December 2020
  54. HAWKES EA, Opat S, Hertzberg M
    Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL.
    J Clin Oncol. 2020;38:4221-4222.

  55. PERSKY DO, Smith SM, LeBlanc ML, Friedberg JW, et al
    Reply to E. Hawkes et al.
    J Clin Oncol. 2020;38:4222-4223.

  56. CRUMP M
    Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma?
    J Clin Oncol. 2020 Dec 4:JCO2002905. doi: 10.1200/JCO.20.02905.

    November 2020
  57. CAPPELL KM, Sherry RM, Yang JC, Goff SL, et al
    Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    J Clin Oncol. 2020;38:3805-3815.
    PubMed     Abstract available

  58. ROSCHEWSKI M, Dunleavy K, Wilson WH
    Reply to M. Hertzberg et al.
    J Clin Oncol. 2020;38:3723-3724.

    October 2020
  59. CROMBIE JL, Armand P
    Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm.
    J Clin Oncol. 2020;38:3565-3574.

  60. JAIN P, Dreyling M, Seymour JF, Wang M, et al
    High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.
    J Clin Oncol. 2020 Oct 19:JCO2002287. doi: 10.1200/JCO.20.02287.

  61. BROCKELMANN PJ, Muller H, Guhl T, Behringer K, et al
    Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
    J Clin Oncol. 2020 Oct 15:JCO2000947. doi: 10.1200/JCO.20.00947.
    PubMed     Abstract available

  62. O'BRIEN MM
    Defining the Optimal Treatment of First Relapse of Pediatric Relapsed Anaplastic Large-Cell Lymphoma: Clinical Trial Challenges for Rare Diagnoses.
    J Clin Oncol. 2020 Oct 15:JCO2002285. doi: 10.1200/JCO.20.02285.

  63. EVENS AM, Parsons SK
    Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality.
    J Clin Oncol. 2020 Oct 8:JCO2002668. doi: 10.1200/JCO.20.02668.

    September 2020
  64. JACOBSON CA, Hunter BD, Redd R, Rodig SJ, et al
    Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
    J Clin Oncol. 2020;38:3095-3106.
    PubMed     Abstract available

  65. GALLAMINI A, Rossi A, Patti C, Picardi M, et al
    Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial.
    J Clin Oncol. 2020 Sep 18:JCO2000935. doi: 10.1200/JCO.20.00935.
    PubMed     Abstract available

  66. DORES GM, Curtis RE, Dalal NH, Linet MS, et al
    Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.
    J Clin Oncol. 2020 Sep 18:JCO2000264. doi: 10.1200/JCO.20.00264.
    PubMed     Abstract available

  67. BROCKELMANN PJ, Borchmann S, Borchmann P, Engert A, et al
    Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche.
    J Clin Oncol. 2020 Sep 18:JCO2002351. doi: 10.1200/JCO.20.02351.

  68. HERTZBERG M, Joske DJL, Gandhi MK
    DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
    J Clin Oncol. 2020 Sep 15:JCO2001850. doi: 10.1200/JCO.20.01850.

    August 2020
  69. JAFFE ES, Feldman AL, Gaulard P, Miranda RN, et al
    Reply to M. Romero et al.
    J Clin Oncol. 2020;38:2819-2820.

    July 2020
  70. KNORR F, Brugieres L, Pillon M, Zimmermann M, et al
    Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
    J Clin Oncol. 2020 Jul 30:JCO2000157. doi: 10.1200/JCO.20.00157.
    PubMed     Abstract available

  71. LUGTENBURG PJ, de Nully Brown P, van der Holt B, D'Amore FA, et al
    Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
    J Clin Oncol. 2020 Jul 30:JCO1903418. doi: 10.1200/JCO.19.03418.
    PubMed     Abstract available

  72. RAMOS CA, Grover NS, Beaven AW, Lulla PD, et al
    Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
    J Clin Oncol. 2020 Jul 23:JCO2001342. doi: 10.1200/JCO.20.01342.
    PubMed     Abstract available

  73. GHESQUIERES H, Salles G
    Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting.
    J Clin Oncol. 2020 Jul 15:JCO2001134. doi: 10.1200/JCO.20.01134.

  74. PERSKY DO, Li H, Stephens DM, Park SI, et al
    Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
    J Clin Oncol. 2020 Jul 13:JCO2000999. doi: 10.1200/JCO.20.00999.
    PubMed     Abstract available

    Longitudinal Assessment of Health-Related Quality of Life Among Survivors of Hodgkin Lymphoma: It Is About Time!
    J Clin Oncol. 2020 Jul 10:JCO2001585. doi: 10.1200/JCO.20.01585.

    June 2020
  76. KREISSL S, Muller H, Goergen H, Meissner J, et al
    Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group.
    J Clin Oncol. 2020 Jun 23:JCO1903160. doi: 10.1200/JCO.19.03160.
    PubMed     Abstract available

  77. FROSCH ZAK, Landsburg DJ
    Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
    J Clin Oncol. 2020;38:2014-2017.

  78. HAYASHI RJ, Winter SS, Dunsmore KP, Devidas M, et al
    Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    J Clin Oncol. 2020 Jun 17:JCO2000531. doi: 10.1200/JCO.20.00531.
    PubMed     Abstract available

  79. ROMERO M, Melo A, Bedoya N, de la Hoz J, et al
    Should Flow Cytometry Be Considered a First Line of Study in the Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma?
    J Clin Oncol. 2020 Jun 17:JCO2000712. doi: 10.1200/JCO.20.00712.

    May 2020
  80. ROSCHEWSKI M, Dunleavy K, Abramson JS, Powell BL, et al
    Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
    J Clin Oncol. 2020 May 26:JCO2000303. doi: 10.1200/JCO.20.00303.
    PubMed     Abstract available

  81. NASTOUPIL LJ, Jain MD, Feng L, Spiegel JY, et al
    Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
    J Clin Oncol. 2020 May 13:JCO1902104. doi: 10.1200/JCO.19.02104.
    PubMed     Abstract available

  82. VAN BESIEN KW, Orfali N
    Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come.
    J Clin Oncol. 2020;38:1501-1504.

    April 2020
  83. FUCHS M, Goergen H, Kobe C, Borchmann P, et al
    Reply to H.J.A. Adams et al.
    J Clin Oncol. 2020;38:1116-1117.

    March 2020
    Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors.
    J Clin Oncol. 2020 Mar 31:JCO2000361. doi: 10.1200/JCO.20.00361.

    February 2020
  85. TOBIN JWD, Keane C, Gunawardana J, Gandhi MK, et al
    Reply to M. Sorigue.
    J Clin Oncol. 2020;38:648-649.

  86. BACHY E, Salles G
    Reply to S. Fuji.
    J Clin Oncol. 2020;38:523.

  87. FUJI S
    Answer to Simulation Analysis of Cost-Effectiveness in 2012 Has Finally Come in 2019.
    J Clin Oncol. 2020;38:522.

  88. MANZ CR, Porter DL, Bekelman JE
    Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies.
    J Clin Oncol. 2020;38:384-387.

    January 2020
  89. KHODADOUST MS, Rook AH, Porcu P, Foss F, et al
    Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome: A Multicenter Phase II Study.
    J Clin Oncol. 2020;38:20-28.
    PubMed     Abstract available

    July 2019
  90. OEFFINGER KC, Ford JS, Moskowitz CS, Chou JF, et al
    Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1900547. doi: 10.1200/JCO.19.00547.
    PubMed     Abstract available

    April 2019
  91. SIKIC BI, Lakhani N, Patnaik A, Shah SA, et al
    First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
    J Clin Oncol. 2019;37:946-953.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.